SYSTEMATIC REVIEW article

Front. Pediatr., 23 August 2023

Sec. Neonatology

Volume 11 - 2023 | https://doi.org/10.3389/fped.2023.1206389

Risk and diagnostic factors and therapy outcome of neonatal early onset sepsis in ICU patients of Saudi Arabia: a systematic review and meta analysis

  • 1. Department of Clinical Pharmacy, King Fahad Medical City Hospital, Riyadh, Saudi Arabia

  • 2. Department of Neonatal Intensive Care Unit, Maternity and Children Hospital, Dammam, Saudi Arabia

  • 3. Department of Pharmacy, Maternity and Children Hospital, Ministry of Health, Jouf, Saudi Arabia

  • 4. Department of Medicine, Ministry of Health, Abha, Saudi Arabia

  • 5. Department of Medicine, Ministry of Health, Khamis Mushait, Saudi Arabia

  • 6. Department of Medicine, King Khaled University, Abha, Saudi Arabia

  • 7. College of Medicine, King Khalid University, Al Fara, Saudi Arabia

  • 8. Department of Pharmacy, Dr. Sulaiman Al-Habib Hospital, Khobar, Saudi Arabia

  • 9. Department of Nursing Office, Hail General Hospital, Hail, Saudi Arabia

  • 10. Department of Pharmacy, Al-Dawaa Medical Services Company Limited, Unaizah, Saudi Arabia

  • 11. Department of Pharmacy, Qassim University Medical City Hospital, Buraidah, Saudi Arabia

Abstract

Background:

Neonatal early onset sepsis (NEOS) is a serious and potentially life-threatening condition affecting newborns within the first few days of life. While the diagnosis of NEOS was based on clinical signs and symptoms in the past, recent years have seen growing interest in identifying specific diagnostic factors and optimizing therapy outcomes. This study aims to investigate the diagnostic and risk factors and therapy outcomes of neonatal EOS in ICU patients in Saudi Arabia, with the goal of improving the management of neonatal EOS in the country.

Methods:

This method outlines the protocol development, search strategy, study selection, and data collection process for a systematic review on neonatal early onset sepsis in Saudi Arabian ICU patients, following the PRISMA 2020 guidelines. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) is a well-established guideline that provides a framework for conducting systematic reviews and meta-analyses in a transparent and standardized manner. It aims to improve the quality and reporting of such research by ensuring clear and comprehensive reporting of study methods, results, and interpretations. The search strategy included electronic databases (PubMed, Embase, Google Scholar, Science Direct, and the Cochrane Library) and manual search of relevant studies, and data were extracted using a standardized form.

Results:

The systematic review included 21 studies on neonatal sepsis in Saudi Arabia, with varying study designs, sample sizes, and prevalence rates of sepsis. Group B streptococcus and E. coli were the most commonly isolated pathogens. Various diagnostic factors and risk factors were reported, including hematological parameters, biomarkers, and blood cultures. The quality of the included studies was assessed using the Newcastle-Ottawa Scale and Joanna Briggs Institute critical checklist.

Conclusions:

The review identified a number of risk and diagnostic factors and therapy outcomes for neonatal sepsis. However, most of the studies were having small scale cohort groups. Further research with controlled study designs is needed to develop effective prevention and management strategies for neonatal sepsis in Saudi Arabia.

1. Introduction

Neonatal early onset sepsis (NEOS) is a serious and potentially life-threatening condition that affects newborns within the first few days of life (, ). It is characterized by systemic infection and inflammation, which can lead to septic shock, multiple organ failure, and death if not promptly and effectively treated (, ). The pathophysiology predominantly involves ascending colonisation of the uterine cavity and maternal vaginal tract by the typical bacterial flora of the genitourinary and gastrointestinal tracts, which leads to eventual colonisation and infection of the foetus or newborn (). NEOS is a major health concern worldwide, with an estimated incidence of 0.5–1.5 cases per 1,000 live births in developed countries, and up to 5 cases per 1,000 live births in low- and middle-income countries (LMICs) (, ). In 3%–4% of newborns who have NEOS, there may be serious systemic disease and even deaths are possible outcomes (, ).

In the past, the diagnosis of NEOS was based on clinical signs and symptoms, such as fever, lethargy, poor feeding, and respiratory distress, and was often treated empirically with broad-spectrum antibiotics (, , ). However, this approach led to overuse of antibiotics, increased healthcare costs, and the emergence of antibiotic-resistant bacteria (). In recent years, there has been growing interest in identifying specific diagnostic factors that can accurately predict the presence or absence of NEOS, and in optimizing therapy outcomes through targeted antibiotic therapy and supportive measures (, ). The risk factors for NEOS include maternal factors such as maternal fever, chorioamnionitis, and prolonged rupture of membranes, as well as neonatal factors such as low birth weight, prematurity, and invasive procedures (, , ). In addition, laboratory parameters such as elevated C-reactive protein (CRP) levels, low platelet count, and abnormal white blood cell (WBC) count have been shown to be useful in predicting the presence of NEOS (, ).

Despite the availability of diagnostic tools and risk stratification algorithms, the management of neonatal EOS remains challenging, particularly in neonatal intensive care unit (NICU) patients (). Guidelines for the prevention of NEOS are provided by the Centers for Disease Control and Prevention (CDC), the American Academy of Pediatrics, and the American Congress of Obstetricians and Gynecologists, and provide algorithms for the diagnosis and management of high risk NEOS patients (, ). These recommendations are based on epidemiological data collected prior to the widespread use of intrapartum antibiotic prophylaxis in obstetrics, when NEOS incidence was 5–10-fold greater than presently found (). These recommendations lead to a significant number (15%–20%) of term and late preterm babies being examined for sepsis and getting 5%–8% of empirical antibiotics (). The optimal duration of antibiotic therapy, the choice of antibiotics, and the use of adjunctive therapies such as intravenous immunoglobulin (IVIG) and granulocyte-colony stimulating factor (G-CSF) remain topics of debate (, 26).

Saudi Arabia is a high-income country with a well-established healthcare system, including specialized NICUs. However, the incidence and outcomes of neonatal EOS in Saudi Arabia, along with other Gulf countries, remain insufficiently characterized (27, 28). Nevertheless, NEOS is a major health concern in neonatal intensive care units (NICUs) in Saudi Arabia. Identifying diagnostic factors and optimizing therapy outcomes are crucial for the management of EOS in these patients. This study aims to investigate the diagnostic factors and therapy outcomes of neonatal EOS in ICU patients in Saudi Arabia. The study explores the clinical presentation of EOS, laboratory parameters, and risk factors associated with the development of EOS. The findings of this study will contribute to improving the management of neonatal EOS in Saudi Arabia and provide insight into optimizing therapy outcomes for this vulnerable patient population.

2. Materials and methods

2.1. Protocol development

The methodology for this study on followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 guidelines to ensure transparent reporting and reduce bias in the study. PRISMA is a well-established guideline that provides a framework for conducting systematic reviews and meta-analyses in a transparent and standardized manner. It aims to improve the quality and reporting of such research by ensuring clear and comprehensive reporting of study methods, results, and interpretations. The study protocol was developed before the commencement of the study, outlining the research question, search strategy, inclusion and exclusion criteria, data collection and analysis methods, and ethical considerations.

2.2. Search strategy

A comprehensive search of electronic databases such as PubMed, Embase, Google Scholar, Science Direct, and the Cochrane Library was conducted to identify studies relevant to the research question. The search included keywords such as “neonatal sepsis,” “early onset sepsis,” “ICU patients,” “diagnostic factors,” “risk factors,” and “therapy outcomes.” The search strategy also include MeSH terms and keywords related to neonatal EOS, ICU patients, and Saudi Arabia. A manual search of the reference lists of relevant studies was also performed. The search strategy was designed by two authors who are expert in this field and reviewed by another research team among co-authors. The details are given in Supplementary Table S1 as supplementary file.

2.3. Study selection

Two independent reviewers screened the titles and abstracts of the identified studies to determine their eligibility for inclusion. The full texts of potentially relevant studies were assessed for eligibility based on predefined inclusion and exclusion criteria. Studies that meet the following criteria were included in the study: (1) conducted in Saudi Arabia, (2) neonates diagnosed with early onset sepsis, (3) admitted to ICU, (4) diagnostic and risk factors and therapy outcomes reported, and (5) observational or interventional studies. Studies that did not meet the inclusion criteria were excluded. Any discrepancies between the reviewers were resolved through discussion and consensus.

2.4. Data collection

Data were extracted from the eligible studies using a standardized data extraction form. The data in Table 1 included information on author and year, location, study period and settings, NEOS definition, study design, sample size and microbiological data on common causative pathogens. In Table 2, information was included related to diagnostic factors (hematological parameters, biomarkers, blood cultures), mother-related risk factors (premature ruptures of membranes, gestational age at delivery, mode of delivery and delivery <37 weeks of gestation), neonate-related risk factor (low apgar score, resuscitation at birth, need for artificial ventilation, low birth weight) and therapy outcome parameters (length of nicu stay, recovery/success rate, change of antibiotics and death). This review was performed between January and April 2023.

Table 1

Author and yearLocationStudy periodSettingsNeonatal definitionStudy designSample SizeTop 3 isolated pathogens
Al-Matary et al., 2019 (27)RiyadhJanuary 2011–December 2015King Fahad Medical City Hospital<72 hRetrospective study245Group B streptococcus (33.3%)E. coli (27.3%)Streptococcus species (12.1%)
Al-Mouqdad et al., 2018 (29)RiyadhJuly 2015–June 2017King Saud Medical CityNot statedRetrospective study295
Al-Rafiaah et al., 2016 (30)Riyadh2014King Abdul Aziz Medical CityNot statedRetrospective study85E. coli (29.4%)Coagulase negative Staphylococcus (23.5%)Group B streptococcus (17.6%)
Al-Zaharani et al., 2015 (31)TaifJanuary 2013–January 2014King Abdul Aziz hospitalNot statedRetrospective study100Klebsiella spp. (28.0%)E. coli (20.0%)Group B streptococcus (12.0%)
Almuneef et al., 2000 (32)RiyadhJanuary 1990–December 1994King Fahad National Guard hospital<7 daysRetrospective study23Group B streptococcus (100%)
Hammoud et al., 2017 (28)TaifJune 2013- May 2015King Abdul Aziz hospital Maternity and children's hospital<72 hProspective study30,389Group B streptococcus (59.8%)E. coli (12.7%)Coagulase negative Staphylococcus (5.9%)
Kilani et al., 2000 (33)RiyadhJanuary 1996–December 1997King Khalid University Hospital<48 hRetrospective study865E. coli (28.6%)MSSA (21.4%)Coagulase negative Staphylococcus (14.3%)
Huseynova et al., 2021 (34)RiyadhFebruary 2020–June 2020King Saud Medical City<72 hRetrospective study44Group B streptococcus (6.8%)
Al-Mudeer et al., 2020 (35)JazanMay 2012–April 2019King Fahad Central Hospital<72 hRetrospective study28,337E. coli (29%)Group B streptococcus (17%)Coagulase negative Staphylococcus (11%)
Luhidan et al., 2019 (36)Riyadh2004–2014King Abdullah Specialized hospital<7 daysRetrospective study55Group B streptococcus (100%)
Sobaih et al., 2014 (37)RiyadhJanuary 1999–December 2007King Khalid University Hospital<72 hRetrospective study468Staphylococcus epidermidis (45%)Staphylococcus aureus (11.8%)Klebsiella pneumoniae (11.8%)
Nasr et al., 2013 (38)TaifMarch 2012–August 2012King Abdul Aziz hospitalNot statedProspective study205
Fattah et al., 2017 (39)RiyadhJanuary 2013–August 2015King Abdul Aziz Medical CityNot statedProspective study320E. coli (68.0%)H. influenzae (27.0%)Group B streptococcus (6.0%)
Dawodu et al., 1997 (40)KhobarSeptember 1983–September 1988King Fahd Hospital<48 hCase-control61Staphylococcus epidermidis (18.0%)Klebsiella Enterobacter Serratia (8.1%)S aureus (3.2%)
Barnawi et al., 2020 (41)MadinaMarch 2019–May 2019Madina Maternity and Children hospitalNot statedCase study1Elizabethkingia meningoseptica (100%)
Haque et al., 1990 (42)RiyadhOctober 1983–July 1988King Khalid University Hospital<48 hRetrospective study190Staphylococcus epidermidis (35.7%)S aureus (17.3%)Klebsiella spp. (9.4%)
Ohlsson et al., 1986 (43)RiyadhNovember 1980–October 1984King Faisal Specialist hospital<48 hRetrospective study49Klebsiella Enterobacter Serratia (21.3%)E. coli (17.6%)S. aureus (15.4%)
Alsohime et al., 2019 (44)RiyadhKing Saud Medical CityNot statedCase study1Actinomyces neuii (100%)
Elbashier et al., 1994 (45)QatifJanuary 1989–January 1992Qatif Central hospital<48 hProspective study144Klebsiella spp. (29.7%)E. coli (21.6%)Pseudomonas spp. (5.4%)
Abu-Osba et al., 1989 (46)DhahranJanuary 1981–December 1986Dhahran Health Center<3 daysRetrospective study76Staphylococcus epidermidis (44.4%)Enterococcus (33.3%)E. coli (30.0%)
Srair et al., 1993 (47)QatifJune 1992–May 1993Qatif Central hospital<72 hProspective study53E. coli (15.1%)Group B streptococcus (11.3%)Streptococcal faecalis (9.4%)

Characteristics of included studies.

Table 2

Author and yearDiagnostic factorsRisk factorsTherapy outcomes
Mother-relatedNeonate-related
Hematological parametersBiomarkersBlood culturesPremature ruptures of membranesGestational age at deliveryMode of deliveryDelivery <37 weeks of gestationLow Apgar scoreResuscitation at birthNeed for artificial ventilationLow birth weightLength of NICU stayRecovery/success rateChange of antibioticsDeath
Al-Matary et al., 2019 (27)
Al-Mouqdad et al., 2018 (29)
Al-Rafiaah et al., 2016 (30)
Al-Zaharani et al., 2015 (31)
Almuneef et al., 2000 (32)
Hammoud et al., 2017 (28)
Kilani et al., 2000 (33)
Huseynova et al., 2021 (34)
Al-Mudeer et al., 2020 (35)
Luhidan et al., 2019 (36)
Sobaih et al., 2014 (37)
Nasr et al., 2013 (38)
Fattah et al., 2017 (39)
Dawodu et al., 1997 (40)
Barnawi et al., 2020 (41)
Haque et al., 1990 (42)
Ohlsson et al., 1986 (43)
Alsohime et al., 2019 (44)
Elbashier et al., 1994 (45)
Abu-Osba et al., 1989 (46)
Srair et al., 1993 (47)
Total1071855775121238511

Diagnostic and risk factors and therapy outcomes of NEOS.

2.5. Meta-analysis

The statistical analysis was performed using RStudio software (RStudio Team, Boston, MA; version R, 2023.03.0) using Meta Package and Metaprop command. The proportion test was performed to estimate the proportion of risk factors. I-squared (I2) index statistic was employed to evaluate the assertiveness heterogeneity in choice of effects, considering the randomized effect for the analysis. A threshold of 0.05 was considered significant.

3. Results

3.1. Included studies

The PRISMA 2020 flow diagram is shown in Figure 1 which is a graphical representation of the systematic review process. It outlines the steps involved in identifying, screening, and selecting studies for inclusion in a review. In this particular study, the review included searches of databases only. The diagram starts with the identification of studies via databases and registers, where 872 records were identified from databases and none from registers. After identifying the records, the next step was to remove duplicate records, which accounted for 289 records. In addition, 201 records were marked as ineligible by automation tools, and 176 records were excluded based on the initial screening of titles and abstracts. These studies did not meet the predefined inclusion criteria for our systematic review. The reasons for exclusion at this stage included irrelevant topics, unrelated interventions, and studies conducted in settings other than Saudi Arabia. Of the remaining 206 screened records, 58 were excluded further during the full-text assessment phase. These exclusions were due to the identification of commentaries, guidelines, and book chapters, which were not eligible for inclusion in our systematic review. The remaining 148 records were sought for retrieval, but 76 records were not retrieved. The 72 retrieved records were assessed for eligibility, where 12 non-English studies, 9 studies with inappropriate interventions, 7 studies with no required data, 17 studies with no full-text, and 6 review articles were excluded. Finally, 21 studies were included in the review. These studies met the eligibility criteria and were included in the systematic review. Figure 2 showed that most of the studies were conducted from Riyadh and eastern provinces of KSA.

Figure 1

Figure 2

The studies used different study designs, including retrospective, prospective, case-control, and case studies, and varied in their neonatal definitions of NEOS, study period, and sample sizes. The Table 1 included the results of 21 different studies on neonatal sepsis conducted in different locations and settings in Saudi Arabia. The studies varied in terms of study design, sample size, and prevalence of neonatal sepsis (NOS). The sample sizes of the studies varied widely, ranging from 1 in case study to 30,389 in prospective study. The larger sample sizes were reported by Al-Mudeer et al. (2020) and Hammoud et al. (2017), both of which had over 28,000 participants. The studies were conducted in different settings, including medical centers, hospitals, and maternity and children's hospitals. The top three isolated pathogens varied across the studies. Group B streptococcus (GBS) and E. coli were the most commonly isolated pathogens, with GBS being the most commonly isolated pathogen in 5 of the 21 studies. Other pathogens that were commonly isolated include Coagulase negative Staphylococcus (CNS), Klebsiella spp., and Staphylococcus epidermidis. The distribution of pathogens in different cities of KSA is presented in Figure 3.

Figure 3

The present study also aimed to investigate the diagnostic and risk factors and therapy outcomes of NEOS in ICU patients in Saudi Arabia as shown in Table 2. The analysis of the results obtained from the 21 selected studies revealed that various factors were used for the diagnosis of EOS, including hematological parameters, biomarkers and blood cultures, The use of hematological parameters, such as white blood cell count, absolute neutrophil count, and immature to total neutrophil ratio, was reported by some studies as a diagnostic factor for EOS. In contrast, biomarkers such as C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6) were reported by several studies as useful tools for the diagnosis of EOS. Blood cultures are considered the gold standard for the diagnosis of NEOS and several studies reported that blood cultures were used as a diagnostic factor for NEOS. Regarding the mother and neonate related risk factors, gestational age at delivery was reported as a significant risk factor for NEOS by some studies. Preterm delivery is known to increase the risk of NEOS due to the immature immune system of preterm infants. Moreover, premature rupture of membranes was reported by some studies as a significant risk factor for EOS. Low Apgar score at birth, need for artificial ventilation, and low birth weight were also reported by some studies as significant risk factors for NEOS. The length of NICU stay was reported as a neonate-related risk factor by some studies. Mode of delivery including vaginal delivery and caesarean section was reported by some studies as a significant risk factor for NEOS. In terms of therapy outcomes, the recovery or success rate of therapy was reported by several studies. The change of antibiotics during treatment was reported by some studies. The overall death rate was reported by most of the studies. Nevertheless, the present study revealed that there is heterogeneity among the diagnostic factors and risk factors reported by the selected studies. This heterogeneity may be due to differences in the study population.

3.2. Meta-analysis

While performing meta-analysis, significant heterogeneity between included studies, as shown by I2 (>90%) was observed, thus all the data were analyzed following random effect models. Overall, the risk factors including mother-related and neonate-related increased the chances of early onset sepsis (EOS). Most of the studies reported that pre-term neonates (95% CI: 0.20–0.50) and low birth weight neonates (95% CI: 0.11–0.44) were at elevated risk of EOS. The detailed results are shown in Table 3 and Figure 4.

Table 3

Risk factorsNo. of studiesSample sizeWeight (%)95% confidence intervalHeterogeneity I2P-value
LCIUCI
Mother-related
Premature rupture of membrane554915.6%0.050.1991%<0.01
Cesarean delivery791819.5%0.180.5298%<0.01
<37 weeks of gestation1095426.1%0.200.5095%<0.01
Neonate-related
Low birth weight101,28526.9%0.110.4497%<0.01
Resuscitation at birth1522.9%0.240.51Not estimatedNot estimated
Need of artificial ventilation32229%0.220.7996%<0.01

Risk factors included in meta-analysis of early onset sepsis.

Figure 4

3.3. Quality assessment

The quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS) for cohort studies and Joanna briggs Institute (JBI) critical checklist for case study. For cohort studies, the NOS was used to assess the methodological quality of each study. This scale evaluates the risk of bias in three domains: selection of study groups, comparability of groups, and the ascertainment of exposure/outcome. Each study is awarded a maximum of nine stars based on its quality in these three domains, with higher scores indicating lower risk of bias. This checklist includes criteria such as clear identification of the problem, description of the context, adequate data analysis, and appropriate conclusions. Each study was evaluated against these criteria to determine its methodological quality any discrepancies between the reviewers were resolved through discussion and consensus. The details are mentioned in Tables 4, 5.

Table 4

ReferenceSelectionComparabilityOutcomesQuality Score
Representative of sampleaSample sizebNon-respondentscAscertainment of exposuredComparability of cohort studies on basis of designeAssessment of outcomesfStatistical analysisg
Al-Matary et al., 2019 (27)******6
Al-Mouqdad et al., 2018 (29)********8
Al-Rafiaah et al., 2016 (30)******6
Al-Zaharani et al., 2015 (31)*******7
Almuneef et al., 2000 (32)********8
Hammoud et al., 2017 (28)*******7
Kilani et al., 2000 (33)******6
Huseynova et al., 2021 (34)********8
Al-Mudeer et al., 2020 (35)******6
Luhidan et al., 2019 (36)********8
Sobaih et al., 2014 (37)*******7
Nasr et al., 2013 (38)*******7
Fattah et al., 2017 (39)*******7
Dawodu et al., 1997 (40)*******7
Haque et al., 1990 (42)*****5
Ohlsson et al., 1986 (43)*****5
Elbashier et al., 1994 (45)*******7
Abu-Osba et al., 1989 (46)******6
Srair et al., 1993 (47)******6

Quality assessment of cohort studies.

a

* = truly representative or somewhat representative of average in target population.

b

* = Drawn from the same community.

c

* = Secured record or structured review.

d

* = Yes, − = No.

e

* = Study controls for age, gender, and other factors.

f

* = Record linkage or blind assessment, ** = Both.

g

* = follow-up of all subjects.

Table 5

StudyQ1Q2Q3Q4Q5Q6Q7Q8Quality rating
Dawodu et al., 1997 (40)YesYesYesYesYesYesNoYesGood
Barnawi et al., 2020 (41)YesYesYesYesYesYesYesYesGood

Quality assessment of case reports.

Q1. Were patient's demographic characteristics clearly described? Q2. Was the patient's history clearly described and presented as a timeline? Q3. Was the current clinical condition of the patient on presentation clearly described? Q4. Were diagnostic tests or assessment methods and the results clearly described? Q5. Was the intervention(s) or treatment procedure(s) clearly described? Q6. Was the post-intervention clinical condition clearly described? Q7. Were adverse events (harms) or unanticipated events identified and described? Q8. Does the case report provide takeaway lessons?

4. Discussion

This systematic review is one of the broadest studies to show the pattern, risk and diagnostic factors, and clinical outcome of newborn with NEOS from Saudi Arabia. Findings of 21 studies were included which are consistent with observations from other research indicating the proportion of NEOS is significantly higher (48, 49). The risk factors identified are similar to other previous studies, focusing on the significance of premature rupture of membrane, premature birth, and low birth weight. According to a study, NEOS is more common in newborns with extremely low birth weights, decreased respiratory function at delivery, and mother related risk factors (50). These results may be explained by preterm babies' weak innate immune system, which increase their risk of developing NEOS (). NEOS develops in the uterus as a result of maternal blood infection or, more frequently because of infection of the placenta and the amniotic fluid (51). Patients may present with fetal distress, pneumonia, newborn asphyxia or sepsis owing to aspiration of contaminated amniotic fluid or secretions after delivery (52). A comprehensive study looked at whether newborn clinical presentation might be used to rule out EOS in babies born to moms who had chorioamnionitis. According to the investigation, EOS can happen in infants who had initially positive clinical status (53). A range of services are available in different healthcare settings included in this review, to manage high-risk newborns who are prone to infection. Nevertheless, in our review, we discovered a variety of variables, including a low Apgar score, in a sizable number of neonates as a risk factor for NEOS. This finding is consistent with other studies that revealed a low Apgar score to be strongly related with newborn sepsis (48, 49, 54). Low Apgar ratings in newborns make them more vulnerable to infection because they are less able to handle stress from outside sources (55). Furthermore, the findings revealed that NEOS patients had low birth weights, which is consistent with a finding from other research (56). The leading maternal risk factors for NEOS were found to be multiparty and caesarean birth. This was also the main maternal risk factor for NEOS according to a research by Al Dasoky et al. in a tertiary care hospital in Jordan (57). A valuable measure of the health of the newborn and the severity of the illness is the total WBC count. Our review revealed that the patients' WBC counts were disturbed which is a sign of a severe illness in the newborn (58). The fact that NEOS occurs while the mother and child are still confined to the hospital and that there is a significant risk of hospital acquired infection (59).

In developed and underdeveloped countries, different pathogens are responsible for causing newborn sepsis including both Gram-negative and positive bacteria (60). Nonetheless, the present initiatives for maternal intrapartum antibiotic prophylaxis against GBS may be responsible for the more prevalence of Gram-negative microbes (61). A variety of pathogens are responsible for neonatal EOS, depending on multiple factors, such as hospital practices, geographical region, and changes in microbial resistance pattern. Overall, Group B streptococcus and E. coli are the leading pathogens for EOS. However, the patterns of pathogens may vary from state to state. According to our findings, GBS was the most prevalent etiologic agent in NEOS, followed by E. coli. Our study reported that Staphylococcus species are responsible for EOS in Khobar, E. coli in Jazan and Klebsiella spp. in Taif. Stoll et al., reported that E. coli associated sepsis was increased from 3.2 to 6.8 per 1,000 live births. Likewise, the most frequently identified agent in NEOS in European countries is GBS, followed by Gram-negative bacilli and staphylococci (62). Moreover, GBS, staphylococci, gram-negative bacteria, and candida were identified in NEOS patients in other regions as well (, , , , 49). According to earlier research that is in line with our results, infant sepsis mortality is also very high and had a mortality rate for NEIOS 10%–20% (63). Neonates are more susceptible to infections in ICU settings because of their immature immune system, and exposure to invasive medical procedures.

To the best our knowledge, this is first systematic review carried out from the KSA and is notable because it represents a comprehensive complete database evaluated to identify the pattern, diagnostic and risk factors, and therapy outcomes of NEOS in different healthcare institutes in KSA. It is crucial to undertake more controlled research studies since neonatal safety is so important. Incidence or prevalence of NEOS in the KSA population must be quantified. Moreover, larger trials are necessary to assess the safety and effectiveness of antibiotic therapy. However, no adverse drug reactions were seen, indicating that even if a negative effect existed, it would likely be rare and would need to be considered in relation to the unfavourable consequences of sepsis assessments and antibiotic exposure. Prior research studies from other parts of world have demonstrated the need of clinical monitoring as a component of any NEOS approach by showing that GBS-specific NEOS persists in children delivered to moms who screen erroneously negative for GBS without additional intrapartum risk factors for EOS (6466). Nonetheless, this systematic review provides a valuable baseline data to start in KSA. Future studies could explore further questions.

5. Conclusions

This systematic review highlighted the various substantial risk factors associated with development of neonatal early onset sepsis in ICU patients. The prevalence of EOS is high in neonates admitted to ICU with multiple maternal and neonatal risk factors. Therefore, by identifying such factors, the healthcare experts can implement targeted preventive strategies and monitor these risk factors, thus reducing the prevalence of EOS and improving the therapeutic outcomes. Moreover, high-quality studies and better diagnostics are required especially in hospitals with high neonatal mortality to evaluate the prevalence of EOS, identify the associated risk factors and clinical outcomes.

Statements

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Conflict of interest

RA was employed by Al-Dawaa Medical Services Company Limited.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped.2023.1206389/full#supplementary-material

References

  • 1.

    SimonsenKAAnderson-BerryALDelairSFDaviesHD. Early-onset neonatal sepsis. Clin Microbiol Rev. (2014) 27(1):2147. 10.1128/CMR.00031-13

  • 2.

    ChackoBSohiI. Early onset neonatal sepsis. Indian J Pediatr. (2005) 72(1):236. 10.1007/BF02760574

  • 3.

    StollBJHansenNFanaroffAAWrightLLCarloWAEhrenkranzRAet alChanges in pathogens causing early-onset sepsis in very-low-birth-weight infants. N Engl J Med. (2002) 347(4):2407. 10.1056/NEJMoa012657

  • 4.

    SchuchatAZywickiSSDinsmoorMJMercerBRomagueraJO'SullivanMJet alRisk factors and opportunities for prevention of early-onset neonatal sepsis: a multicenter case-control study. Pediatrics. (2000) 105(1):216. 10.1542/peds.105.1.21

  • 5.

    GlaserMAHughesLMJnahANewberryDHarris-HamanPA. Neonatal sepsis: a review of pathophysiology and current management strategies. Adv Neonatal Care. (2021) 21(1):4960. 10.1097/ANC.0000000000000769

  • 6.

    BrayeKet alEpidemiology of neonatal early-onset sepsis in a geographically diverse Australian health district 2006-2016. PloS One. (2019) 14(4):e0214298. 10.1371/journal.pone.0214298

  • 7.

    JoshiNSHuynhKLuTLeeHCFrymoyerA. Epidemiology and trends in neonatal early onset sepsis in California, 2010–2017. J Perinatol. (2022) 42(7):9406. 10.1038/s41372-022-01393-7

  • 8.

    WestonEJPondoTLewisMMMartell-ClearyPMorinCJewellBet alThe burden of invasive early-onset neonatal sepsis in the United States, 2005–2008. Pediatr Infect Dis J. (2011) 30(11):937. 10.1097/INF.0b013e318223bad2

  • 9.

    StollBJHansenNISánchezPJFaixRGPoindexterBBVan MeursKPet alEarly onset neonatal sepsis: the burden of group B streptococcal and E. coli disease continues. Pediatrics. (2011) 127(5):81726. 10.1542/peds.2010-2217

  • 10.

    RodwellRLLeslieALTudehopeDI. Early diagnosis of neonatal sepsis using a hematologic scoring system. J Pediatr. (1988) 112(5):7617. 10.1016/S0022-3476(88)80699-1

  • 11.

    GriffinMPMoormanJR. Toward the early diagnosis of neonatal sepsis and sepsis-like illness using novel heart rate analysis. Pediatrics. (2001) 107(1):97104. 10.1542/peds.107.1.97

  • 12.

    DadgostarP. Antimicrobial resistance: implications and costs. Infect Drug Resist. (2019) 12:390310. 10.2147/IDR.S234610

  • 13.

    StockerMvan HerkWEl HelouSDuttaSSchuermanFAvan den Tooren-de GrootRKet alC-reactive protein, procalcitonin, and white blood count to rule out neonatal early-onset sepsis within 36h: a secondary analysis of the neonatal procalcitonin intervention study. Clin Infect Dis. (2021) 73(2):e38390. 10.1093/cid/ciaa876

  • 14.

    SnoekLvan KasselMNKrommenhoekJFAchtenNBPlötzFBvan SorgeNMet alNeonatal early-onset infections: comparing the sensitivity of the neonatal early-onset sepsis calculator to the Dutch and the updated NICE guidelines in an observational cohort of culture-positive cases. EClinicalMedicine. (2022) 44. 10.1016/j.eclinm.2021.101270

  • 15.

    OddieSEmbletonND. Risk factors for early onset neonatal group B streptococcal sepsis: case-control study. Br Med J. (2002) 325(7359):308. 10.1136/bmj.325.7359.308

  • 16.

    KlingerGLevyISirotaLBoykoVReichmanBLerner-GevaLet alEpidemiology and risk factors for early onset sepsis among very-low-birthweight infants. Am J Obstet Gynecol. (2009) 201(1):38.e16. 10.1016/j.ajog.2009.03.006

  • 17.

    StollBJHansenNIHigginsRDFanaroffAADuaraSGoldbergRet alVery low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the national institute of child health and human development neonatal research network, 2002–2003. Pediatr Infect Dis J. (2005) 24(7):6359. 10.1097/01.inf.0000168749.82105.64

  • 18.

    FilecciaLWoodTGuthrieARonohCSleethCKamath-RayneBDet alComparison of early-onset sepsis risk-stratification algorithms in neonates in a Kenyan nursery. Hosp Pediatr. (2022) 12(10):87684. 10.1542/hpeds.2021-006228

  • 19.

    American College of Obstetricians and Gynecologists. ACOG committee opinion No. 485. Prevention of earlyonset group B streptococcal disease in newborns. Obstet Gynecol. (2011) 117(4):101927. 10.1097/AOG.0b013e318219229b

  • 20.

    VeraniJRMcGeeLSchragSJ. Prevention of perinatal group B streptococcal disease: revised guidelines from CDC, 2010. MMWR Recomm Rep. (2010) 59(RR-10):136.

  • 21.

    PuopoloKMEichenwaldEC. No change in the incidence of ampicillin-resistant, neonatal, early-onset sepsis over 18 years. Pediatrics. (2010) 125(5):e10318. 10.1542/peds.2009-1573

  • 22.

    MooreMRSchragSJSchuchatA. Effects of intrapartum antimicrobial prophylaxis for prevention of group-B-streptococcal disease on the incidence and ecology of early-onset neonatal sepsis. Lancet Infect Dis. (2003) 3(4):20113. 10.1016/S1473-3099(03)00577-2

  • 23.

    BizzarroMJRaskindCBaltimoreRSGallagherPG. Seventy-five years of neonatal sepsis at Yale: 1928–2003. Pediatrics. (2005) 116(3):595602. 10.1542/peds.2005-0552

  • 24.

    KuzniewiczMWWalshEMLiSFischerAEscobarGJ. Development and implementation of an early-onset sepsis calculator to guide antibiotic management in late preterm and term neonates. Jt Comm J Qual Patient Saf. (2016) 42(5):2329. 10.1016/S1553-7250(16)42030-1

  • 25.

    PolinRA. Management of neonates with suspected or proven early-onset bacterial sepsis. Pediatrics. (2012) 129(5):100615. 10.1542/peds.2012-0541

  • 26.

    RhodesAEvansLEAlhazzaniWLevyMMAntonelliMFerrerRet alSurviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. (2017) 43(3):30477. 10.1007/s00134-017-4683-6

  • 27.

    Al-MataryAHeenaHAlSarheedASOudaWAlShahraniDAWaniTAet alCharacteristics of neonatal sepsis at a tertiary care hospital in Saudi Arabia. J Infect Public Health. (2019) 12(5):66672. 10.1016/j.jiph.2019.03.007

  • 28.

    HammoudMSAl-TaiarAAl-AbdiSYBozaidHKhanAAlMuhairiLMet alCulture-proven early-onset neonatal sepsis in Arab states in the gulf region: two-year prospective study. Int J Infect Dis. (2017) 55:115. 10.1016/j.ijid.2016.12.006

  • 29.

    Al-MouqdadMMAljobairFAlaklobiFATahaMYAbdelrahimAAsfourSSet alThe consequences of prolonged duration of antibiotics in premature infants with suspected sepsis in a large tertiary referral hospital: a retrospective cohort study. Int J Pediatr Adolesc Med. (2018) 5(3):1105. 10.1016/j.ijpam.2018.08.003

  • 30.

    AlrafiaahASAl ShaalanMAlshammariFOAlmohaisaniAABawazirASOmairAet alNeonatal sepsis in a tertiary care hospital in Saudi Arabia. Int J Adv Res. (2016) 4:171320. 10.21474/IJAR01/2265

  • 31.

    Al-ZahraniAKGhonaimMMHusseinYMEedEMKhalifaASDorghamLSet alEvaluation of recent methods versus conventional methods for diagnosis of early-onset neonatal sepsis. J Infect Dev Ctries. (2015) 9(04):38893. 10.3855/jidc.5950

  • 32.

    AlmuneefMAlalolaSAhmedSMemishZKhanMYAlshaalanMet alThe changing spectrum of group B streptococcal (GBS) infection in infants of Saudi Arabia. J Chemother. (2000) 12(1):4852. 10.1179/joc.2000.12.1.48

  • 33.

    KilaniRABasamadM. Pattern of proven bacterial sepsis in a neonatal intensive care unit in Riyadh-Saudi Arabia: a 2-year analysis. J Med Liban. (2000) 48(2):7783. .

  • 34.

    HuseynovaRMahmoudLBAljobairFHHuseynovOJaganathanPPAbdelrahimAet alUse of early-onset sepsis risk calculator for neonates ≥34 weeks in a large tertiary neonatal centre, Saudi Arabia. Cureus. (2021) 13(4). 10.7759/cureus.14620

  • 35.

    AlmudeerAHAlibrahimMAGosadiIM. Epidemiology and risk factors associated with early onset neonatal sepsis in the south of KSA. J Taibah Univ Medical Sci. (2020) 15(6):50914. 10.1016/j.jtumed.2020.08.009

  • 36.

    Al LuhidanLMadaniAAlbanyanEAAl SaifSNasefMAlJohaniSet alNeonatal group B streptococcal infection in a tertiary care hospital in Saudi Arabia: a 13-year experience. Pediatr Infect Dis J. (2019) 38(7). 10.1097/INF.0000000000002269

  • 37.

    SobaihBHAl-MandeelH. Early and late onset neonatal sepsis in very low birth weight infants in a tertiary center in Saudi Arabia. J Neonatal Biol. (2014) 3(5):24. 10.4172/2167-0897.1000159

  • 38.

    NasrAAllamGAl-ZahraniAAlsulaimaniA. Neonatal infections in Saudi Arabia: association with C-reactive protein, CRP -286 (C>T>A) gene polymorphism and IgG antibodies. BMC Immunol. (2013) 14(1):38. 10.1186/1471-2172-14-38

  • 39.

    FattahMAAl FadhilAOAsaifSManluluRKararTAhmedAet alUtility of cytokine, adhesion molecule and acute phase proteins in early diagnosis of neonatal sepsis. J Nat Sci Biol Med. (2017) 8(1):32. 10.4103/0976-9668.198362

  • 40.

    DawoduAAl UmranKTwum-DansoK. A case control study of neonatal sepsis: experience from Saudi Arabia. J Trop Pediatr. (1997) 43(2):848. 10.1093/tropej/43.2.84

  • 41.

    BarnawiAIKordyFNAlmuwalladOKKassarahKA. Early neonatal sepsis and meningitis caused by Elizabethkingia meningoseptica in Saudi Arabia. Saudi Med J. (2020) 41(7):753. 10.15537/smj.2020.7.25720

  • 42.

    HaqueKNChagiaAHShaheedMM. Half a decade of neonatal sepsis, Riyadh, Saudi Arabia. J Trop Pediatr. (1990) 36(1):203. 10.1093/tropej/36.1.20

  • 43.

    OhlssonABaileyTTakieddineF. Changing etiology and outcome of neonatal septicemia in Riyadh, Saudi Arabia. Acta Pædiatrica. (1986) 75(4):5404. 10.1111/j.1651-2227.1986.tb10246.x

  • 44.

    AlsohimeFAssiriRAAl-ShahraniFBakeetHElhazmiMSomilyAMet alPremature labor and neonatal sepsis caused by Actinomyces neuii. J Infect Public Health. (2019) 12(2):2824. 10.1016/j.jiph.2018.04.001

  • 45.

    ElbashierAMAbusrairHOwaJA. Aetiology of neonatal septicaemia in Qatif, Saudi Arabia. Early Child Dev Care. (1994) 98(1):318. 10.1080/0300443940980104

  • 46.

    Abu-OsbaYKMallouhAAHannRWTolleyS. Pattern of and risk factors for neonatal sepsis in Saudi Arab newborn. J Obstet Gynaecol. (1989) 10(sup1):S234. 10.3109/01443618909151292

  • 47.

    SrairHAOwaJAEl-BashierAMAmanH. Genital flora, prolonged rupture of the membranes and the risk of early onset neonatal septicemia in Qatif Central Hospital, Kingdom of Saudi Arabia. Early Child Dev Care. (1993) 93(1):7985. 10.1080/0030443930930108

  • 48.

    SundaramVKumarPDuttaSMukhopadhyayKRayPGautamVet alBlood culture confirmed bacterial sepsis in neonates in a north Indian tertiary care center: changes over the last decade. Jpn J Infect Dis. (2009) 62(1):4650. 10.7883/yoken.JJID.2009.46

  • 49.

    JabiriAWellaHLSemionoASariaAProtasJ. Prevalence and factors associated with neonatal sepsis among neonates in Temeke and Mwananyamala Hospitals in Dar es Salaam, Tanzania. Tanzan J Health Res. (2016) 18(4). 10.4314/thrb.v18i4.4

  • 50.

    NaherHKhamaelA. Neonatal sepsis; the bacterial causes and the risk factors. Int Res J Medical Sci. (2013) 1(6):1922.

  • 51.

    NewtonER. Chorioamnionitis and intraamniotic infection. Clin Obstet Gynecol. (1993) 36(4):795808. 10.1097/00003081-199312000-00004

  • 52.

    De CuntoAPaviottiGDemariniS. Neonatal aspiration: not just meconium. J Neonatal Perinatal Med. (2013) 6(4):3557. 10.3233/NPM-1372613

  • 53.

    WorthamJMHansenNISchragSJHaleEVan MeursKSánchezPJet alChorioamnionitis and culture-confirmed, early-onset neonatal infections. Pediatrics. (2016) 137(1). 10.1542/peds.2015-2323

  • 54.

    AdataraPAfayaASaliaSMAfayaRAKonlanKDAgyabeng-FandohEet alRisk factors associated with neonatal sepsis: a case study at a specialist hospital in Ghana. Sci World J. (2019) 2019. 10.1155/2019/9369051

  • 55.

    CnattingiusSJohanssonSRazazN. Apgar score and risk of neonatal death among preterm infants. N Engl J Med. (2020) 383(1):4957. 10.1056/NEJMoa1915075

  • 56.

    HaqueKN. Definitions of bloodstream infection in the newborn. Pediatr Crit Care Med. (2005) 6(3):S459. 10.1097/01.PCC.0000161946.73305.0A

  • 57.

    Al DasokyHAAl AwayshehFNKaplanNMAl RimawiHAAghaRAbu-SettehMet alRisk factors for neonatal sepsis in tertiary hospital in Jordan. JRMS. (2009) 16(3):169.

  • 58.

    HornikCPBenjaminDKBeckerKCBenjaminDKJrLiJClarkRHet alUse of the complete blood cell count in early-onset neonatal sepsis. Pediatr Infect Dis J. (2012) 31(8):799802. 10.1097/INF.0b013e318256905c

  • 59.

    SrivastavaSShettyN. Healthcare-associated infections in neonatal units: lessons from contrasting worlds. J Hosp Infect. (2007) 65(4):292306. 10.1016/j.jhin.2007.01.014

  • 60.

    BasAYDemirelNZencirogluAGölNTanirGet alNosocomial blood stream infections in a neonatal intensive care unit in Ankara, Turkey. Turk J Pediatr. (2010) 52(5):464.

  • 61.

    SchragSJZywickiSFarleyMMReingoldALHarrisonLHLefkowitzLBet alGroup B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med. (2000) 342(1):1520. 10.1056/NEJM200001063420103

  • 62.

    GerdesJS. Diagnosis and management of bacterial infections in the neonate. Pediatric Clinics. (2004) 51(4):93959. 10.1016/j.pcl.2004.03.009

  • 63.

    TurhanEEGürsoyTOvalıF. Factors which affect mortality in neonatal sepsis. Turk Arch Pediatr. (2015) 50(3):170. 10.5152/TurkPediatriArs.2015.2627

  • 64.

    EscobarGJPuopoloKMWiSTurkBJKuzniewiczMWWalshEMet alStratification of risk of early-onset sepsis in newborns ≥34 weeks’ gestation. Pediatrics. (2014) 133(1):306. 10.1542/peds.2013-1689

  • 65.

    PuopoloKMMadoffLCEichenwaldEC. Early-onset group B streptococcal disease in the era of maternal screening. Pediatrics. (2005) 115(5):12406. 10.1542/peds.2004-2275

  • 66.

    Van DykeMKPharesCRLynfieldRThomasARArnoldKECraigASet alEvaluation of universal antenatal screening for group B streptococcus. N Engl J Med. (2009) 360(25):262636. 10.1056/NEJMoa0806820

Summary

Keywords

risk factors, diagnostic factors, therapy outcome, neonatal early onset sepsis, ICU patients, Saudi Arabia

Citation

Alshammari MK, Alsanad AH, Alnusayri RJ, Alanazi AS, Shamakhi FQ, Alshahrani KM, Alshahrani AM, Yahya G, Alshahrani AA, Alshahrani TS, Sultan HS, Alshahrani FM, Alreshidi FA, Alnigaidan RA and Almazyad AA (2023) Risk and diagnostic factors and therapy outcome of neonatal early onset sepsis in ICU patients of Saudi Arabia: a systematic review and meta analysis. Front. Pediatr. 11:1206389. doi: 10.3389/fped.2023.1206389

Received

15 April 2023

Accepted

03 August 2023

Published

23 August 2023

Volume

11 - 2023

Edited by

Shi Yuan, Children’s Hospital of Chongqing Medical University, China

Reviewed by

Nie Chuan, Guangdong Women and Children Hospital, China Muhammad Fawad Rasool, Bahauddin Zakariya University, Pakistan

Updates

Copyright

*Correspondence: Mohammed K. Alshammari

ORCID Mohammed K. Alshammari orcid.org/0000-0001-6687-0461 Abdulmajeed S. Alanazi orcid.org/0009-0006-1890-9679 Fatmah Q. Shamakhi orcid.org/0009-0008-4686-1320 Khaled M. Alshahrani orcid.org/0009-0008-5192-7902 Abdullah M. Alshahrani orcid.org/0009-0008-1213-4870 Ghaliah Yahya orcid.org/0009-0009-4715-8909 Abdulaziz A. Alshahrani orcid.org/0009-0005-9410-1375 Turki S. Alshahrani orcid.org/0009-0002-4991-4105 Hamad S. Sultan orcid.org/0009-0000-3750-3144

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics